Acitretin
From Wikipedia, the free encyclopedia
Acitretin
|
|
Systematic (IUPAC) name | |
9-(4-methoxy-2,3, 6-trimethyl-phenyl)- 3,7-dimethyl-nona-2,4,6,8- tetraenoic acid | |
Identifiers | |
CAS number | |
ATC code | D05 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C21H26O3 |
Mol. mass | 326.429 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Acitretin (trade name Soriatane®) is a second generation retinoid. It is taken orally, and is typically used for psoriasis.
It is a metabolite of etretinate, which was used prior to the introduction of acitretin. Etretinate was discontinued because it had a narrow therapeutic index as well as a long elimination half-life (t1/2=120 days), making dosing difficult. In contrast, acitretin's half-life is approximately 2 days.
Women must avoid becoming pregnant for at least 3 years after discontinuing acitretin. In comparison, etretinate was not recommended at all for women who planned to become pregnant.
Acitretin - Alitretinoin - Bexarotene - Etretinate - Fenretinide - Isotretinoin - Retinaldehyde - Tazarotene - Vitamin A (Retinol, Tretinoin)